# CLAIMS

[Claim 1]

An oxaliplatin-encapsulating liposome aqueous dispersion comprising an external aqueous phase that contains 2-morpholinoethanesulfonic acid, wherein the liposomes comprise, as a liposome component, hydrogenated purified soybean phosphatidylcholines.

[Claim 2]

The oxaliplatin-encapsulating liposome aqueous dispersion according to claim 1, wherein the dispersion comprises an internal aqueous phase that substantially contains no 2-morpholinoethanesulfonic acid.

[Claim 3]

The oxaliplatin-encapsulating liposome aqueous dispersion according to claim 1 or 2, wherein the dispersion has a pH of 6.0 to 7.0.

[Claim 4]

The oxaliplatin-encapsulating liposome aqueous dispersion according to any one of claims 1 to 3, wherein liposomes comprise at least one saturated phospholipid as a liposome component.

[Claim 5]

The oxaliplatin-encapsulating liposome aqueous dispersion according to any one of claims 1 to 4, wherein the amount of 2-morpholinoethanesulfonic acid is 0.00001 to 10 parts by mass per part by mass of liposome-forming phospholipid.

[Claim 6]

Use of 2-morpholinoethanesulfonic acid or a salt thereof as stabilizer for an oxaliplatin-encapsulating liposome aqueous dispersion, wherein the liposomes comprise, as a liposome component, hydrogenated purified soybean phosphatidylcholines.

[Claim 7]

The use according to claim 6, wherein the dispersion

has a pH of 6.0 to 7.0.

[Claim 8]

A method for stabilizing an oxaliplatin-encapsulating liposome aqueous dispersion, comprising adding 2-morpholinoethanesulfonic acid or a salt thereof to the oxaliplatin-encapsulating liposome aqueous dispersion, wherein the liposomes comprise, as a liposome component, hydrogenated purified soybean phosphatidylcholines.

[Claim 9]

The method according to claim 8, wherein the dispersion has a pH of 6.0 to 7.0.

[Claim 10]

A pharmaceutical composition comprising the oxaliplatin-encapsulating liposome aqueous dispersion according to any one of claims 1 to 5.

[Claim 11]

The oxaliplatin-encapsulating liposome aqueous dispersion according to any one of claims 1 to 5, for use in a method of treating cancer.

[Claim 12]

The oxaliplatin-encapsulating liposome aqueous dispersion according to any one of claims 1 to 5, for use as an antitumor effect potentiator for use in a method of enhancing antitumor activity of an antitumor agent.